Reports

Sale

Age-Related Macular Degeneration (AMD) Market

Global Age-Related Macular Degeneration Market Size, Report: By Product: Wet AMD, Dry AMD; By Drug: Lucentis, Eylea, Avastin, Others; By Route of Administration: Intravenous, Intravitreal; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis, Key Indicators for Demand; Competitive Landscape; 2024-2032

Global Age-Related Macular Degeneration (AMD) Market Outlook

The global age-related macular degeneration (AMD) market stood at USD 2.04 billion in 2023 and is projected to reach USD 4.40 billion by 2032, growing at CAGR of 8.9% between 2024 and 2032.

 

Global Age-Related Macular Degeneration (AMD) Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The age-related macular degeneration (AMD) is a disease in which the macula of the eye’s small central region of the retina deteriorates. The macula is considered to be an essential component of the retina, as it regulates the visual perception of the eye. The ability of an individual to read, identify and recognize objects that require immaculate visual details determine macular health.

 

Market Segmentation

Usually, after the age of sixty, there is an onset of an eye disease that can gradually destroy the macula, the middle part of the retina, further impairing the central vision of the eye. Age-related macular degeneration (AMD) causes rare blindness as it affects the centre of the eye.

 

Global Age-Related Macular Degeneration (AMD) Market By Drug

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The age-related macular degeneration (AMD) industry can be divided based on segments such as product, drug, route of administration, and region.

The industry can be broadly categorised on the basis of product into:

  • Wet AMD
  • Dry AMD

The industry can be divided based on the drug into:

  • Lucentis
  • Eylea
  • Avastin
  • Others

The industry can be divided on the basis of route of administration into:

  • Intravenous
  • Intravitreal

The EMR report looks into the regional markets of age-related macular degeneration (AMD) like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific regions.

 

Global Age-Related Macular Degeneration (AMD) Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The enhanced reimbursement incentives for age-related macular degeneration (AMD) drugs add to the development of the industry. In addition, the age-related macular degeneration market is driven by an increase in the incidence of eye-related disorders and growth in the global geriatric population. Although the growing use of off-label medications and the availability of off-label treatments hinder the industry growth, the rising market trends, such as the advancement of gene therapy for age-related macular degeneration, will result in the growth of the medical therapy of age-related macular degeneration.

Just a few licensed drugs are available for the treatment of the disorder in the market. The related side-effects are also severe to the consumer’s health. Therefore, the need for safe and innovative drugs to treat age-related macular degeneration remains substantially unmet. This has culminated in several drug firms focusing on gene therapy to treat the disease. Intravitreal injection administered gene therapy does not affect the cells. It also protects and enhances the vision of patients. Such advantages will drive demand for gene therapy, which during the forecast period, will have a positive impact on the industry growth globally.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global age-related macular degeneration (AMD) market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bayer AG 
  • F. Hoffmann-La Roche Ltd. 
  • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
  • Novartis AG 
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment

  • Product
  • Drug
  • Route of Administration
  • Region
Breakup by Product
  • Wet AMD
  • Dry AMD
Breakup by Drug
  • Lucentis
  • Eylea
  • Avastin
  • Others
Breakup by Route of Administration
  • Intravenous
  • Intravitreal
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs. 
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Age-Related Macular Degeneration (AMD) Market Analysis
    8.1    Key Industry Highlights
    8.2    Global Age-Related Macular Degeneration (AMD) Historical Market (2018-2023) 
    8.3    Global Age-Related Macular Degeneration (AMD) Market Forecast (2024-2032)
    8.4    Global Age-Related Macular Degeneration (AMD) Market by Product
        8.4.1    Wet AMD
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Dry AMD
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
    8.5    Global Age-Related Macular Degeneration (AMD) Market by Drug
        8.5.1    Lucentis
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Eylea
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Avastin
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Others
    8.6    Global Age-Related Macular Degeneration (AMD) Market by Route of Administration 
        8.6.1    Intravenous
            8.6.1.1    Historical Trend (2018-2023)
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Intravitreal
            8.6.2.1    Historical Trend (2018-2023)
            8.6.2.2    Forecast Trend (2024-2032)
    8.7    Global Age-Related Macular Degeneration (AMD) Market by Region     
        8.7.1    North America
            8.7.1.1    Historical Trend (2018-2023) 
            8.7.1.2    Forecast Trend (2024-2032)
        8.7.2    Europe
            8.7.2.1    Historical Trend (2018-2023) 
            8.7.2.2    Forecast Trend (2024-2032)
        8.7.3    Asia Pacific
            8.7.3.1    Historical Trend (2018-2023) 
            8.7.3.2    Forecast Trend (2024-2032)
        8.7.4    Latin America
            8.7.4.1    Historical Trend (2018-2023) 
            8.7.4.2    Forecast Trend (2024-2032)
        8.7.5    Middle East and Africa
            8.7.5.1    Historical Trend (2018-2023) 
            8.7.5.2    Forecast Trend (2024-2032)
9    North America Age-Related Macular Degeneration Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Age-Related Macular Degeneration Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5   Others
11    Asia Pacific Age-Related Macular Degeneration Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Age-Related Macular Degeneration Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Age-Related Macular Degeneration Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive  Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Bayer AG
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    F. Hoffmann-La Roche Ltd. 
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Novartis AG
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Age-Related Macular Degeneration (AMD) Market: Key Industry Highlights, 2018 and 2032
2.    Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Product (USD Billion), 2018-2023
3.    Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Product (USD Billion), 2024-2032
4.    Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Drug (USD Billion), 2018-2023
5.    Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Drug (USD Billion), 2024-2032
6.    Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Route of Administration (USD Billion), 2018-2023
7.    Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Route of Administration (USD Billion), 2024-2032
8.    Global Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Region (USD Billion), 2018-2023
9.    Global Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Region (USD Billion), 2024-2032
10.    North America Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
11.    North America Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
12.    Europe Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
13.    Europe Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
14.    Asia Pacific Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
15.    Asia Pacific Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
16.    Latin America Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
17.    Latin America Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
18.    Middle East and Africa Age-Related Macular Degeneration (AMD) Historical Market: Breakup by Country (USD Billion), 2018-2023
19.    Middle East and Africa Age-Related Macular Degeneration (AMD) Market Forecast: Breakup by Country (USD Billion), 2024-2032
20.    Global Age-Related Macular Degeneration (AMD) Market Structure

Key Questions Answered in the Report

In 2023, the global age-related macular degeneration (AMD) market attained a value of nearly USD 2.04 billion.

The market is projected to grow at a CAGR of 8.9% between 2024 and 2032.

The market is estimated to witness a moderate growth in the forecast period of 2024-2032 to reach about USD 4.40 billion by 2032.

The major drivers of the industry, such as the enhanced reimbursement policies, increasing prevalence of eye-related disorders amongst the geriatric population, increasing demand for enhanced healthcare facilities, and the growing technological advancements, are expected to aid the market growth.

The key market trends guiding the growth of the age-related macular degeneration (AMD) industry include the growing preference for intravitreal injection administered gene therapy and increasing clinical trials.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Wet AMD and dry AMD are the leading products of age-related macular degeneration (AMD) in the industry.

The major drug segments in the industry include Lucentis, Eylea, and Avastin, among others.

The significant routes of administration available in the industry include intravenous and intravitreal.

The major players in the industry are Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), among others.

Analyst Review

The global age-related macular degeneration (AMD) market attained a value of about USD 2.04 billion in 2023, driven by the rising prevalence of eye-related disorders and technological advancements. Aided by the growing demand for gene therapy, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 8.9%. The market is projected to reach nearly USD 4.40 billion by 2032.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on products, the industry can be bifurcated into wet AMD and dry AMD. On the basis of drug type, the market is divided into Lucentis, Eylea, and Avastin, among others. By route of administration, the industry is categorised into intravenous and intravitreal. The major regional markets for age-related macular degeneration (AMD) are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER